GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » COGS-to-Revenue

Genor Biopharma Holdings (HKSE:06998) COGS-to-Revenue : 0.01 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Genor Biopharma Holdings COGS-to-Revenue?

Genor Biopharma Holdings's Cost of Goods Sold for the six months ended in Dec. 2024 was HK$1.1 Mil. Its Revenue for the six months ended in Dec. 2024 was HK$204.7 Mil.

Genor Biopharma Holdings's COGS to Revenue for the six months ended in Dec. 2024 was 0.01.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Genor Biopharma Holdings's Gross Margin % for the six months ended in Dec. 2024 was 99.48%.

Genor Biopharma Holdings COGS-to-Revenue Historical Data

The historical data trend for Genor Biopharma Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genor Biopharma Holdings COGS-to-Revenue Chart

Genor Biopharma Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial 0.25 - 0.06 - 0.01

Genor Biopharma Holdings Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 - - 0.02 0.01

Genor Biopharma Holdings COGS-to-Revenue Calculation

Genor Biopharma Holdings's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1.432 / 220.185
=0.01

Genor Biopharma Holdings's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1.059 / 204.736
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genor Biopharma Holdings  (HKSE:06998) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Genor Biopharma Holdings's Gross Margin % for the six months ended in Dec. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 1.059 / 204.736
=99.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Genor Biopharma Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Genor Biopharma Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Genor Biopharma Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » COGS-to-Revenue
Comparable Companies
HKSE:02511 HKSE:01875 HKSE:03681 HKSE:06622 HKSE:02137 HKSE:02566 HKSE:02563 HKSE:01244 HKSE:06978 HKSE:02898 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
67N:Germany
Address
690 Bibo Road, Room 501-02, Building 6, Pudong New District, Shanghai, CHN, 201203
Website
https://www.genorbio.com
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
Executives
Forebright New Opportunities Fund, L.p. 2101 Beneficial owner
Forbright Global Limited 2201 Interest of corporation controlled by you
Fnof Gp Limited 2201 Interest of corporation controlled by you
Deg – Deutsche Investitions- Und Entwicklungsgesellschaft Mbh 2101 Beneficial owner
Hsg Growth V Holdco Q, Ltd. 2101 Beneficial owner
Hsg Holding Limited 2201 Interest of corporation controlled by you
Snp China Enterprises Limited 2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund Management I, L.p. 2201 Interest of corporation controlled by you
Shen Nan Peng 2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund I, L.p. 2101 Beneficial owner
Hongshan Capital Growth Fund V, L.p. 2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p. 2201 Interest of corporation controlled by you
Hongshan Capital Management I, L.p. 2201 Interest of corporation controlled by you
Hongshan Capital I, L.p. 2101 Beneficial owner
Ni Xin 2101 Beneficial owner

Genor Biopharma Holdings Headlines

No Headlines